Table of Contents
The new report “Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019” by Spearhead Acuity Business Research & Consulting group reveals that the North America continued to lead global anti-bacterial drugs market with a share of 38.9% in 2014 that translated into revenues worth US$ 16,907.3 million.
The report analyzes the global anti-bacterial drugs market in six regions of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa. The global anti-bacterial market is inclined towards North America and Europe. The majority can be attributed to large volume generic sales as well as a strongest innovative R&D activity in the sector with a large number of companies such as Cubist Pharmaceuticals, Cempra, Actelion, Achaogen and Melinta. Europe and Asia-Pacific followed with market shares of 24.7% and 18.7% respectively. Asia-Pacific is expected to overtake Europe with expirations of several drugs that will be absorbed by the strong generics market by the end of this decade. China remains the largest supplier of raw materials and active moiety to drug manufacturers over the world. With emerging countries such as India and China, the Asia-Pacific region is expected to remain a major threat to innovators and originator companies developing new drugs.
In light of the recent violent clashes throughout different regions of Europe and unpredicted future in conflict regions such as Ukraine and Syria have taken considerable toll in investments for healthcare and progress. There are several initiatives that continue to support the development such as the New Drugs for Bad Bugs (ND4BB) initiative and the IMI-funded COMBACTE project, which aims to give antibiotic drug development a much-needed boost by pioneering new ways of designing and implementing efficient clinical trials for novel antibiotics. These initiatives will drive the innovation of the drugs market in coming years. Price fixing also tends to restrict revenues in the region and other challenges include regulatory hurdles such that new drugs need to show non-inferiority in clinical trials within a margin of 10% as compared with current gold standards.
This report covers major anti-bacterial drug brands by 18 major companies such as Merck & Co, Pfizer Inc, Cubist Pharmaceuticals, Cempra Pharmaceuticals, Astrazeneca, Forest Pharmaceuticals, Actavis, Johnson & Johnson (Janssen Pharma), Mpex Pharmaceuticals Inc, GlaxoSmithKline plc, Takeda, Durata Pharmaceuticals, Targanta, Nektar, Paratek, The Medicines Company, Melinta and Optimer. This exhaustive report covers existing brands such as Cubicin (daptomycin), Teflaro/Zinforo (ceftaroline), Dificid (fidaxomicin), Dalvance (dalbavancin), Orbactiv (oritavancin), Sivextro (tedizolid), Zerbaxa (ceftolozane + tazobactam), Avycaz (ceftazidime-avibactam), Zyvox (linezolid), Avelox (moxifloxacin), Augmentin (amoxicillin + clavulanic acid), Zosyn/Tazocin (piperacillin + tazobactam), Invanz (ertapenem), Tygacil (tigecyline). The scope also covers analysis of stage three and stage two pipeline drugs such as Surotomycin, Solitaire (solithromycin), Delafloxacin, Plazomycin, Taksta (fusidic acid), Cadazolid, Carbavance, Eravacycline, Finafloxacin, Omadacycline, Zabofloxacin, Ramoplanin, Nemonoxacin and Relebactam (MK-7655).
Until recently, the anti-bacterial pipeline was considered to be completely dry with very few foreseen launches, however 2014-2015 saw five major launches with another 8 expected by the turn of the decade. The largest challenge for drug manufacturers was to overcome a barrage of highly drug-resistant superbugs that have been observed across hospitals across the world. Improper usage, dosage and treatment regimen followed by patients has now created significant damage in terms of health since drug-resistant bacteria are difficult to deal with using conventional pharmaceuticals. Consistent investment in research and development particularly by early-clinical stage companies has been successful in delivering a sustainable pipeline for the market. Several companies such as Cellceutix have expanded into the anti-bacterial market after discovery of effective lead compounds against highly difficult to treat pan-drug resistant microbes. Macrolides are expected to become the fastest growing segment within the anti-bacterial space in coming years.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Use this report to: - Assess market dynamics of Chinese market for both communicable and - non-communicable infectious disease drugs, their opportunities and restraints. - Evaluate Chinese drug market ...
Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market Summary Respiratory complications are a ...